Effect of chronic lithium administration on endothelium-dependent relaxation in rat aorta. 2000

A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Iran. ardeh@nrcgeb.ac.ir

1. The effects of chronic lithium administration on the relaxant responses of rat thoracic aortic rings in the presence of indomethacin (a cyclo-oxygenase inhibitor) and/or NG-nitro-L-arginine (L-NOARG; a nitric oxide synthase inhibitor) to acetylcholine (ACh) or sodium nitroprusside were investigated in the present study. 2. Acetylcholine produced a concentration-dependent relaxation in vessels precontracted by phenylephrine (PE), while in lithium-treated rats the maximal relaxation was significantly increased. 3. Indomethacin (20 mumol/L) significantly potentiated the ACh-induced relaxation in lithium-treated and control rats. 4. NG-Nitro-L-arginine (1 mumol/L) decreased the ACh-induced relaxation in both control and lithium-treated rats. In contrast, indomethacin (20 mumol/L) reversed the inhibitory effect of L-NOARG. 5. Sodium nitroprusside produced similar concentration-dependent relaxations of vessels from both control and lithium-treated rats, which was not affected by indomethacin. In endothelium-denuded rings, indomethacin (20 mumol/L) caused a rightward shift in the concentration-contraction curve to PE. 6. These data support evidence for a possible increase in endothelium-dependent relaxation induced by ACh during long-term administration of lithium in rat aortic rings.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000109 Acetylcholine A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. 2-(Acetyloxy)-N,N,N-trimethylethanaminium,Acetilcolina Cusi,Acetylcholine Bromide,Acetylcholine Chloride,Acetylcholine Fluoride,Acetylcholine Hydroxide,Acetylcholine Iodide,Acetylcholine L-Tartrate,Acetylcholine Perchlorate,Acetylcholine Picrate,Acetylcholine Picrate (1:1),Acetylcholine Sulfate (1:1),Bromoacetylcholine,Chloroacetylcholine,Miochol,Acetylcholine L Tartrate,Bromide, Acetylcholine,Cusi, Acetilcolina,Fluoride, Acetylcholine,Hydroxide, Acetylcholine,Iodide, Acetylcholine,L-Tartrate, Acetylcholine,Perchlorate, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D001011 Aorta The main trunk of the systemic arteries. Aortas
D014664 Vasodilation The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE. Vasodilatation,Vasorelaxation,Vascular Endothelium-Dependent Relaxation,Endothelium-Dependent Relaxation, Vascular,Relaxation, Vascular Endothelium-Dependent,Vascular Endothelium Dependent Relaxation
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
October 2007, Canadian journal of physiology and pharmacology,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
March 1991, Pharmacology & toxicology,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
January 1994, Masui. The Japanese journal of anesthesiology,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
September 1995, General pharmacology,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
August 1987, Diabetes,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
August 2004, Anaesthesia and intensive care,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
January 2007, BJU international,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
August 2002, British journal of pharmacology,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
January 2005, Acta pharmacologica Sinica,
A R Dehpour, and H Aghadadashi, and P Ghafourifar, and F Roushanzamir, and M H Ghahremani, and F Meysamee, and N Rassaee, and A Koucharian
August 1996, Shock (Augusta, Ga.),
Copied contents to your clipboard!